文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

高危局限性前列腺癌立体定向放疗联合或不联合选择性淋巴结照射的随机可行性试验(SPORT试验)

A Randomized Feasibility Trial of Stereotactic Prostate Radiation Therapy With or Without Elective Nodal Irradiation in High-Risk Localized Prostate Cancer (SPORT Trial).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-03-08

30例不利中危或高危局限性前列腺癌患者随机1:1接受前列腺-only SABR(P-SABR)或前列腺+盆腔淋巴结SABR(PPN-SABR),目标招募达成且全部完成治疗。两组急性≥2级GI和GU毒性分别为0%和6.7%(P-SABR)、6.7%和20.0%(PPN-SABR);3年晚期≥2级GI和GU毒性分别为6.7%和6.7%(P-SABR)、13.3%和33.3%(PPN-SABR)。γH2AX焦点、淋巴细胞计数和瓜氨酸水平与照射体积及毒性相关,提示潜在预测生物标志物价值。

要点

  • P-SABR组急性≥2级GI和GU毒性分别为0%和6.7%,PPN-SABR组分别为6.7%和20.0%。
  • 3年晚期≥2级GI和GU毒性P-SABR组均为6.7%,PPN-SABR组分别为13.3%和33.3%。
  • PPN-SABR组1例发生晚期3级GU毒性(膀胱炎和血尿),未观察到其他≥3级毒性。

核心结论

  • 比较P-SABR与PPN-SABR的随机试验可行且毒性可接受。
  • γH2AX焦点、淋巴细胞计数和瓜氨酸水平与照射体积及毒性的相关性提示其作为预测生物标志物的潜力。
  • 本研究为英国一项多中心随机3期临床试验提供了依据。

研究设计与样本

  • 随机可行性试验,30例成人男性不利中危或高危局限性前列腺癌患者1:1随机接受P-SABR或PPN-SABR。
  • 入组条件为至少具备以下1项特征:临床磁共振成像分期T3a N0 M0、Gleason评分≥7(4+3)、前列腺特异性抗原>20 ng/mL。
  • P-SABR患者接受36.25 Gy/5次/29天,PPN-SABR患者盆腔淋巴结接受25 Gy/5次,最终队列对前列腺内优势病灶加量至45至50 Gy。
  • 量化磷酸化γ-H2AX(γH2AX)焦点数、瓜氨酸水平和循环淋巴细胞计数。
  • 急性毒性(常见不良事件评价标准第4.03版)在每个治疗周及6周和3个月时收集;医师报告的晚期放射治疗肿瘤学组(RTOG)毒性记录从SABR完成后90天至36个月;患者报告的生活质量(扩展前列腺癌指数综合评分和国际前列腺症状评分)在每个毒性时间点记录。

主要发现

  • 目标招募达成,所有患者均成功完成治疗。
  • 急性≥2级GI和GU毒性:P-SABR组分别为0%和6.7%,PPN-SABR组分别为6.7%和20.0%。
  • 3年晚期≥2级GI和GU毒性:P-SABR组分别为6.7%和6.7%,PPN-SABR组分别为13.3%和33.3%。
  • PPN-SABR组1例患者发生晚期3级GU毒性(膀胱炎和血尿),未观察到其他≥3级毒性。
  • 晚期扩展前列腺癌指数综合评分肠道和泌尿汇总评分出现最小临床重要变化的比例:P-SABR组分别为33.3%和60%,PPN-SABR组分别为64.3%和92.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to establish the feasibility of a randomized clinical trial comparing SABR with prostate-only (P-SABR) or with prostate plus pelvic lymph nodes (PPN-SABR) in patients with unfavorable intermediate- or high-risk localized prostate cancer and to explore potential toxicity biomarkers. METHODS AND MATERIALS: Thirty adult men with at least 1 of the following features were randomized 1:1 to P-SABR or PPN-SABR: clinical magnetic resonance imaging stage T3a N0 M0, Gleason score ≥7 (4+3), and prostate-specific antigen >20 ng/mL. P-SABR patients received 36.25 Gy/5 fractions/29 days, and PPN-SABR patients received 25 Gy/5 fractions to pelvic nodes, with the final cohort receiving a boost to the dominant intraprostatic lesion of 45 to 50 Gy. Phosphorylated gamma-H2AX (γH2AX) foci numbers, citrulline levels, and circulating lymphocyte counts were quantified. Acute toxicity information (Common Terminology Criteria for Adverse Events, version 4.03) was collected weekly at each treatment and at 6 weeks and 3 months. Physician-reported late Radiation Therapy Oncology Group (RTOG) toxicity was recorded from 90 days to 36 months postcompletion of SABR. Patient-reported quality of life (Expanded Prostate Cancer Index Composite and International Prostate Symptom Score) scores were recorded with each toxicity time point. RESULTS: The target recruitment was achieved, and treatment was successfully delivered in all patients. A total of 0% and 6.7% (P-SABR) and 6.7% and 20.0% (PPN-SABR) experienced acute grade ≥2 gastrointestinal (GI) and genitourinary (GU) toxicity, respectively. At 3 years, 6.7% and 6.7% (P-SABR) and 13.3% and 33.3% (PPN-SABR) had experienced late grade ≥2 GI and GU toxicity, respectively. One patient (PPN-SABR) had late grade 3 GU toxicity (cystitis and hematuria). No other grade ≥3 toxicity was observed. In addition, 33.3% and 60% (P-SABR) and 64.3% and 92.9% (PPN-SABR) experienced a minimally clinically important change in late Expanded Prostate Cancer Index Composite bowel and urinary summary scores, respectively. γH2AX foci numbers at 1 hour after the first fraction were significantly higher in the PPN-SABR arm compared with the P-SABR arm (P = .04). Patients with late grade ≥1 GI toxicity had significantly greater falls in circulating lymphocytes (12 weeks post-radiation therapy, P = .01) and a trend toward higher γH2AX foci numbers (P = .09) than patients with no late toxicity. Patients with late grade ≥1 bowel toxicity and late diarrhea experienced greater falls in citrulline levels (P = .05). CONCLUSIONS: A randomized trial comparing P-SABR with PPN-SABR is feasible with acceptable toxicity. Correlations of γH2AX foci, lymphocyte counts, and citrulline levels with irradiated volume and toxicity suggest potential as predictive biomarkers. This study has informed a multicenter, randomized, phase 3 clinical trial in the United Kingdom.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Houlihan OA, Redmond K, Fairmichael C, et al. A Randomized Feasibility Trial of Stereotactic Prostate Radiation Therapy With or Without Elective Nodal Irradiation in High-Risk Localized Prostate Cancer (SPORT Trial). Int J Radiat Oncol Biol Phys. 2023. PMID: 36893820. doi:10.1016/j.ijrobp.2023.02.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。